Revision of bioequivalence test standards eyed

Published: 2002-10-02 06:56:00

Updated: 2002-10-02 06:56:00

The Korea Food and Drug Administration has finished drafting a revision of bioequivalence test standards, which includes a provision for allowing pharmaceutical firms to perform the bioequivalence tests by utilizing their own R&D facilities and human resources in order to ensure the cost-saving e...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK